Envista Holdings Co. (NYSE:NVST) Receives Consensus Rating of "Hold" from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST - Get Free Report) have been assigned a consensus rating of "Hold" from the fifteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $20.18.

A number of brokerages have recently commented on NVST. Needham & Company LLC reissued a "hold" rating on shares of Envista in a research report on Thursday, March 6th. UBS Group cut their price target on shares of Envista from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Monday, March 10th. Wells Fargo & Company set a $19.00 price objective on Envista in a report on Saturday, March 8th. Jefferies Financial Group upped their target price on Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a report on Thursday, January 23rd. Finally, Piper Sandler raised their price target on Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd.

Institutional Trading of Envista

Several hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Envista by 0.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 425,502 shares of the company's stock worth $8,408,000 after acquiring an additional 3,199 shares during the last quarter. XTX Topco Ltd acquired a new stake in Envista during the 3rd quarter worth approximately $704,000. M&T Bank Corp boosted its stake in Envista by 42.9% in the 3rd quarter. M&T Bank Corp now owns 15,945 shares of the company's stock valued at $315,000 after purchasing an additional 4,787 shares during the period. Vestcor Inc grew its holdings in Envista by 344.4% in the 3rd quarter. Vestcor Inc now owns 54,249 shares of the company's stock valued at $1,072,000 after buying an additional 42,041 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Envista by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company's stock worth $57,233,000 after buying an additional 71,435 shares during the period.

Remove Ads

Envista Stock Down 0.5 %

NYSE NVST traded down $0.09 during trading hours on Wednesday, reaching $15.46. 2,446,183 shares of the company's stock were exchanged, compared to its average volume of 2,489,884. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of -2.38, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. The company's 50-day moving average is $18.41 and its two-hundred day moving average is $19.35. Envista has a one year low of $14.22 and a one year high of $23.00.

Envista (NYSE:NVST - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, analysts forecast that Envista will post 1 EPS for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.